Previous reports have demonstrated that in PBC, EZH2 expression was significantly increased in malignant tumors, and was associated with a larger tumor size, ER- and PR-negative status, TNBC, advanced stage disease and reduced progression-free survival and OS [17, 28, 29]. This evidence concerns the gene PGR and neoplasm.